Reviews of INTERCEPT & Pathogen Inactivation

Pathogen Inactivation Technology Reviews

  • Allain JP, Bianco C, Blajchman MA et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005;19(2):110-26.
    > View abstract
     
  • Corash L. Pathogen Reduction Technology: Methods, Status of Clinical Trials, and Future Prospects. Curr Hematol Rep 2003;2(6):495-502.
    > View abstract

Specific Blood Safety Issues & Applications of Pathogen Inactivation

Bacteria

  • Blajchman MA, Beckers EA, Dickmeiss E et al. Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev 2005;19(4):259-72.
    > View abstract
     
  • Corash L. Bacterial contamination of platelet components: prevalence and measures to prevent transfusion-transmitted bacterial infection. In: Scharf RE (ed). Progress and Challenges in Transfusion Medicine, Hemostasis and Hemotherapy. Freiburg i.Br., Karger, 2008: pp 234–47.
    > View abstract
     
  • Corash L.  Bacterial Contamination of Platelet Components:  Solutions To Prevent Transfusion Related Sepsis.  Expert Reviews in Hematology 2011;4(5):509-525.
    > View abstract

CMV

  • Ljungman P.  Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Br J Haematol 2004; 125(2):107-16.
    > View article

TA-GVHD

  • Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004;33(1):1-7.
    > View abstract
     
  • Lin L, Corash L, Osselaer JC.  Protection Against TA-GVHD in Platelet Transfusion by Pathogen Inactivation with the INTERCEPT Blood System™ - Gamma Irradiation is Not the Only Answer.  Haematologica 2010;95(Extra 1):86-93.
     
  • Schlenke P.  Protection against transfusion-associated graft-versus-host disease in blood transfusion: is gamma-irradiation the only answer?  Transfusion Medicine and Hemotherapy 2004;31(Suppl. 1):24-31.
    > View abstract

INTERCEPT Blood System Reviews

Platelets & Plasma

  • Irsch J, Lin L.  Pathogen Inactivation of Platelet and Plasma Components for Transfusion using the INTERCEPT Blood System. Transfusion Medicine and Hemotherapy 2011;38:19-31.
    > View article
     
  • Wollowitz S.  Targeting DNA and RNA in pathogens: mode of action of amotosalen HCl. Transfusion Medicine and Hemotherapy 2004;31(Suppl. 1):11-16.
    > View abstract
     
  • Wollowitz S.  Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001;38(4 Suppl 11):4-11.
    > View abstract

Platelets

  • Lin L.  Psoralen photochemical treatment of platelets.  Science and Medicine 1998;5(1):54-63.
    > View abstract
     
  • Lin L, Alfonso R, Behrman B et al.  Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusions. Transfusion Medicine and Hemotherapy 1998;25(1):39-48.
    > View citation
     
  • Lin L, Cook DN, Wiesehahn GP, et al.  Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light.  Transfusion 1997;37(4):423-35.
    > View abstract
     
  • Liu W, Cimino GD, Corash L et al.  The extent of amotosalen photoconversion during the photochemical treatment process correlates with the level of pathogen inactivation. Transfusion 2011;51(1):52-61.
    > View article
     
  • Schlenke P, Kirchner H, Corash L.  Concerning Caspari et al: pathogen inactivation of cellular blood products – more security for the patient or less? Transfusion Medicine and Hemotherapy 2005;32(1):45-48.
    > View citation

Plasma

  • Singh Y, Sawyer LS, Pinkoski LS, et al.  Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006;46(7):1168-77.
    > View abstract

RBC

  • Henschler R, Seifried E, Mufti N.  Development of the S-303 Pathogen Inactivation Technology for Red Blood Cells Concentrates.  Transfusion Medicine & Hemotherapy. 2011; 38(1):33-42.
    > View abstract
     
  • Mufti N, Erickson AC, North AK et al.  Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Journal Biologicals 2010;38(1):14-19.
    > View abstract
Untitled Document